Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
|Slideshows|December 2, 2019
Year in Review: 2019 Special Reports in Psychiatry
Author(s)Heidi Anne Duerr, MPH, Laurie Martin
As varied as the field of psychiatry itself, our Special Report collections covered issues such as eating disorders, traumatic brain injury, practice management, schizophrenia and depression, complex medical comorbidities, and more. Here's a sampling.
Advertisement
Advertisement
Related to this article
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Advertisement
Advertisement